TP53 and cancer: A recent study analyzed 1,338 Chinese high-risk breast cancer patients who tested mutation negative by a four-gene panel (BRCA1, BRCA2, PTEN and TP53) and found that pathogenic variants in cancer predisposition genes beyond BRCA1, BRCA2, PTEN and TP53 were detected in an additional 4.6% of patients using a multigene panel, with PALB2 (1.4%), RAD51D (0.8%) and ATM (0.8%) being the most commonly mutated genes (Kwong et al., 2020).